Patients achieving a reduction from baseline of at least 10%, 15%, and 20% were confirmatory secondary outcomes in the STEP 1 to STEP 3 studies, and the differences between semaglutide and placebo were statistically significant at each of these thresholds, across all of the studies (Table 23)
Glantzounis, G., Tsimoyiannis, E., Kappas, A
This restriction is based on preclinical findings indicating a potential association with C-cell proliferation
Remaining hydrated is also important, so make sure you drink water
Another scenario is a patient who has been using a GLP-1 therapy for a few years, has reached a weight-loss plateau, and is now in the maintenance phase of treatment
Compounded GLP-1 medication Semaglutide is a GLP-1 receptor agonist that helps regulate appetite and food intake